Ipsen S.A./€IPN
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Ipsen S.A.
Ipsen S.A. is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. The company focuses on the development and commercialization of innovative medicines in targeted therapeutic areas such as oncology, neuroscience, and rare diseases. Ipsen's key products include Somatuline, a treatment for neuroendocrine tumors and acromegaly, and Dysport, used for movement disorders and aesthetic indications. Founded in 1929 by Henri Beaufour, Ipsen has since expanded its presence worldwide, with a strategic emphasis on specialty care and the development of differentiated products. The company leverages its scientific expertise and research capabilities to sustain its competitive position in the biopharmaceutical industry.
Ticker
€IPN
Sector
Primary listing
PAR
Employees
5,358
Headquarters
Website
Ipsen S.A. Metrics
BasicAdvanced
€10B
22.64
€5.37
0.19
€1.40
1.15%
Price and volume
Market cap
€10B
Beta
0.19
52-week high
€123.92
52-week low
€86.78
Average daily volume
39K
Dividend rate
€1.40
Financial strength
Current ratio
1.984
Quick ratio
1.695
Long term debt to equity
19.811
Total debt to equity
22.735
Dividend payout ratio (TTM)
25.90%
Interest coverage (TTM)
36.76%
Profitability
EBITDA (TTM)
1,333
Gross margin (TTM)
83.32%
Net profit margin (TTM)
11.91%
Operating margin (TTM)
27.28%
Effective tax rate (TTM)
20.64%
Revenue per employee (TTM)
€700,000
Management effectiveness
Return on assets (TTM)
9.58%
Return on equity (TTM)
10.89%
Valuation
Price to earnings (TTM)
22.637
Price to revenue (TTM)
2.674
Price to book
2.38
Price to tangible book (TTM)
7.54
Price to free cash flow (TTM)
16.901
Free cash flow yield (TTM)
5.92%
Free cash flow per share (TTM)
7.195
Dividend yield (TTM)
1.15%
Forward dividend yield
1.15%
Growth
Revenue change (TTM)
9.45%
Earnings per share change (TTM)
-34.09%
3-year revenue growth (CAGR)
8.42%
10-year revenue growth (CAGR)
10.26%
3-year earnings per share growth (CAGR)
-15.39%
10-year earnings per share growth (CAGR)
12.24%
3-year dividend per share growth (CAGR)
5.27%
10-year dividend per share growth (CAGR)
5.12%
Bulls say / Bears say
Ipsen reported H1 2025 total sales growth of 11.4% at constant exchange rates, core operating income up 21.9%, and expanded core margin by 3.6 points, prompting an upgrade to full-year guidance of >7% sales growth and >32% margin (Nasdaqturn1search0)
The Rare Disease segment surged 95.7% in H1 2025, with high-margin products Iqirvo and Bylvay delivering double-digit growth (Bylvay +63% YoY), underscoring Ipsen’s successful focus on niche specialty care (Nasdaqturn1search0turn3search1)
On 23 July 2025, the European Commission approved Cabometyx for previously treated advanced neuroendocrine tumors—Ipsen’s sixth indication for the drug—broadening its oncology franchise and diversifying revenue streams (Nasdaqturn1search0)
Somatuline, Ipsen’s long‐standing revenue driver, faces increasing generic competition in the U.S. and Europe, which management expects will negatively impact sales and margins in the second half of 2025 (Nasdaqturn1search0)
Ipsen’s future growth heavily depends on late‐stage clinical readouts for fidrisertib (FALKON trial) and its long‐acting neurotoxin (LANTIC trial), with negative or delayed results posing substantial downside risk to pipeline valuation and revenue forecasts (AInvestturn6search2)
On an IFRS basis, Ipsen’s FY 2024 consolidated net profit plunged 46.3% year-on-year to €347.3 m, reflecting impairments and non-core charges that signal volatility in reported earnings and potential impacts on cash flow (Ipsen Press Releaseturn7search1)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ipsen S.A. stock?
Ipsen S.A. (IPN) has a market cap of €10B as of October 26, 2025.
What is the P/E ratio for Ipsen S.A. stock?
The price to earnings (P/E) ratio for Ipsen S.A. (IPN) stock is 22.64 as of October 26, 2025.
Does Ipsen S.A. stock pay dividends?
Yes, the Ipsen S.A. (IPN) stock pays dividends to shareholders. As of October 26, 2025, the dividend rate is €1.4 and the yield is 1.15%. Ipsen S.A. has a payout ratio of 25.9% on a trailing twelve-month basis.
When is the next Ipsen S.A. dividend payment date?
The next Ipsen S.A. (IPN) dividend payment date is unconfirmed.
What is the beta indicator for Ipsen S.A.?
Ipsen S.A. (IPN) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.